| Zacks Company Profile for Halozyme Therapeutics, Inc. (HALO : NSDQ) |
|
|
| |
| • Company Description |
| Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company also licenses its novel drug delivery technology, ENHANZE. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing subcutaneous formulation of their currently marketed drugs. It also recognizes revenues from sale of drug products to its collaboration partners for development of drugs using its ENHANZE platform. The company also has one approved product in its portfolio, Hylenex recombinant as an adjuvant to facilitate subcutaneous fluid administration. Although Halozyme has one marketed product, it derives the majority of its revenues from royalties on sales of partnered drugs.
Number of Employees: 350 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $53.84 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 2,867,050 shares |
| Shares Outstanding: 123.22 (millions) |
| Market Capitalization: $6,634.22 (millions) |
| Beta: 1.15 |
| 52 Week High: $70.51 |
| 52 Week Low: $42.01 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-0.02% |
-4.14% |
| 12 Week |
-11.23% |
-22.21% |
| Year To Date |
12.61% |
6.36% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
12390 EL CAMINO REAL
-
SAN DIEGO,CA 92130
USA |
ph: 858-794-8889
fax: 858-704-8311 |
ir@halozyme.com |
http://www.halozyme.com |
|
|
| |
| • General Corporate Information |
Officers
Helen I. Torley - President and Chief Executive Officer
Jeffrey W. Henderson - Chairman
Nicole LaBrosse - Senior Vice President and Chief Financial Officer
Bernadette Connaughton - Director
Barbara Duncan - Director
|
|
Peer Information
Halozyme Therapeutics, Inc. (CORR.)
Halozyme Therapeutics, Inc. (RSPI)
Halozyme Therapeutics, Inc. (CGXP)
Halozyme Therapeutics, Inc. (BGEN)
Halozyme Therapeutics, Inc. (GTBP)
Halozyme Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 40637H109
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
|
|
Share - Related Items
Shares Outstanding: 123.22
Most Recent Split Date: (:1)
Beta: 1.15
Market Capitalization: $6,634.22 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $1.34 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $5.16 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: 29.00% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/25 |
|
|
|
| |
